F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic Cancer

Objective:To prospectively compare the accuracy of combined positron emission tomography/computed tomography using 18F-fluorodeoxyglucose (FDG-PET/CT), multidetector row computed tomography (MDCT), and magnetic resonance imaging (MRI) in the evaluation of patients with suspected pancreatic malignancy. Summary Background Data:FDG-PET/CT imaging is increasingly used for staging of pancreatic cancer. Preliminary data suggest a significant influence of FDG-PET/CT on treatment planning, although its role is still evolving. Methods:Thirty-eight consecutive patients with suspicion of pancreatic malignancy were enrolled. Patients underwent a protocol including FDG-PET/CT, MDCT, and MRI combined with magnetic resonance cholangiopancreatography, all of which were blindly evaluated. The findings were confirmed macroscopically at operation and/or by histopathologic analysis (n = 29) or follow-up (n = 9). Results of TNM classification of different imaging methods were compared with clinical TNM classification. Results:Pancreatic adenocarcinoma was diagnosed in 17 patients, neuroendocrine tumor in 3, mass-forming pancreatitis in 4, cystic lesion in 6, and fibrosis in 2. Six patients had a finding of a normal pancreas. The diagnostic accuracy of FDG-PET/CT for pancreatic malignancy was 89%, compared with 76% and 79% for MDCT and MRI, respectively. In the differential diagnosis of suspected malignant biliary stricture at endoscopic retrograde cholangiopancreaticography (n = 21), FDG-PET/CT had a positive predictive value of 92%. In 17 patients with advanced pancreatic adenocarcinoma, FDG-PET/CT had a sensitivity of 30% for N- and 88% for M-staging. Both MDCT and MRI had sensitivities of 30% for N- and 38% for M-staging. Furthermore, the clinical management of 10 patients (26%) was altered after FDG-PET/CT. Conclusion:FDG-PET/CT was more sensitive than conventional imaging in the diagnosis of both primary pancreatic adenocarcinoma and associated distant metastases. In contrast, the sensitivity of FDG-PET/CT was poor in detecting local lymph node metastasis, which would have been important for an assessment of resectability. We recommend the use of FDG-PET/CT in the evaluation of diagnostically challenging cases, especially in patients with biliary strictures without evidence of malignancy in conventional imaging.

[1]  T. Saga,et al.  Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  B. Turner International Union Against Cancer (UICC) , 1999 .

[3]  H. Maeta,et al.  Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  Michael Bouvet,et al.  An Evidence-Based Approach to the Diagnosis and Staging of Pancreatic Cancer , 2005, Pancreatology.

[5]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  W. Chapman,et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  W. Heindel,et al.  Diagnostic impact of 18F-FDG PET–CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  G. Glatting,et al.  Values and Limitations of 18F-Fluorodeoxyglucose–Positron-Emission Tomography with Preoperative Evaluation of Patients with Pancreatic Masses , 2000, Pancreas.

[10]  N. Hosten,et al.  Combined imaging techniques for pancreatic cancer , 2000, The Lancet.

[11]  P. Ell,et al.  Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.

[12]  R. Coleman,et al.  The National Oncologic PET Registry (NOPR): Design and Analysis Plan , 2007, Journal of Nuclear Medicine.

[13]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[14]  S. Hauptmann,et al.  F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.

[15]  Thomas Beyer,et al.  Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  H. Amthauer,et al.  Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  H. Sakahara,et al.  Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.

[18]  F. Chierichetti,et al.  18-Fluorodeoxyglucose Positron Emission Tomography Enhances Computed Tomography Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2007, Annals of surgery.

[19]  E. Hatano,et al.  Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. , 2008, Journal of hepato-biliary-pancreatic surgery.

[20]  K. Hirakawa,et al.  Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. , 2001, International journal of oncology.

[21]  S. Yachida,et al.  Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. , 2008, World journal of gastroenterology.

[22]  J. Neoptolemos,et al.  Positron Emission Tomography Does Not Add to Computed Tomography for the Diagnosis and Staging of Pancreatic Cancer , 2005, Digestive Surgery.

[23]  P. Veit-Haibach,et al.  Contrast-Enhanced 18F-FDG PET/CT: 1-Stop-Shop Imaging for Assessing the Resectability of Pancreatic Cancer , 2008, Journal of Nuclear Medicine.

[24]  M. Schäfer,et al.  Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness , 2005, Annals of surgery.

[25]  M. Malafa,et al.  PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms , 2008, Annals of Surgical Oncology.

[26]  M. Schwaiger,et al.  Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations , 2000, World Journal of Surgery.

[27]  F. Chierichetti,et al.  18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma , 2003, Journal of Gastrointestinal Surgery.

[28]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[29]  Y. Nishiyama,et al.  Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer , 2005, Annals of nuclear medicine.

[30]  S. Reske,et al.  False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? , 1998, European journal of nuclear medicine.

[31]  C. Swain,et al.  Three-Dimensional Linear Endoscopic Ultrasound—Feasibility of a Novel Technique Applied for the Detection of Vessel Involvement of Pancreatic Masses , 2005, The American Journal of Gastroenterology.

[32]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[33]  H. Amthauer,et al.  Detection of Recurrent Pancreatic Cancer: Comparison of FDG-PET with CT/MRI , 2005, Pancreatology.

[34]  W. Oyen,et al.  FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis , 2005, European Journal of Nuclear Medicine and Molecular Imaging.